A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

This study is testing an experimental drug called STK-012 to see if it can help the immune system better fight advanced non-small cell lung cancer. By combining this new treatment with standard therapies, researchers hope to find more effective ways to treat cancers that haven't responded well to common medications.

This trial is for adults with advanced non-squamous non-small cell lung cancer who have not yet received systemic drug treatment. Specifically, it focuses on patients whose tumors test negative for a protein called PD-L1 or have a specific genetic mutation called STK11.

Participants will receive either the new drug alone or in combination with standard treatments like chemotherapy and immunotherapy. Doctors will closely monitor your health, tumor response, and how you feel throughout the study to ensure your safety and track progress.

The study is currently recruiting patients at medical centers in Tucson, Arizona, and Beverly Hills and Fullerton, California. You should speak with your oncologist to see if a nearby location is the right fit for your care.